Company profile
PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Rezatapopt | phase1 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06054464 | phase1 | completed | 2023-09-19 | 2023-11-03 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants |
| NCT06362642 | phase1 | completed | 2024-03-28 | 2024-10-22 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants |
| NCT07372625 | phase1 | recruiting | 2026-02-04 | 2027-03-01 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. |
| NCT05523687 | phase1 | completed | 2022-09-06 | 2022-11-30 | PMV Pharmaceuticals, Inc | AME Study of [14C]-PC14586 in Healthy Male Participants |
| NCT05249348 | phase1 | completed | 2021-12-20 | 2022-06-09 | PMV Pharmaceuticals, Inc | Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers |
FDA applications (0)
No records yet.